CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Pazopanib (5mg/ml)drug
Likely dose
Pazopanib (5mg/ml)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01257750
NCT01257750Phase 2Completed

Safety and Efficacy of Topical Pazopanib in Treatment of Corneal Neovascularization

Reza Dana, MD·interventional·Posted Dec 10, 2010·Updated Jan 18, 2018

In Brief

A Phase 2 clinical trial evaluating Pazopanib (5mg/ml) for Corneal Neovascularization. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safety and efficacy of a drug \[Pazopanib (Votrient)\] as a treatment for corneal neovascularization. The cornea is the clear, central portion of the eye and neovascularization means blood vessel growth. The cornea is typically avascular, or without blood vessels. Corneal neovascularization in the cornea and can put vision at risk. Numerous diseases of the cornea such as inflammation, ischemia (restriction of blood supply), infection, degeneration (or deterioration), trauma, or corneal stem cell deficiency can lead to corneal neovascularization. This major ocular complication can lead to corneal scarring, edema (swelling), lipid deposits, and inflammation that may significantly alter your vision. In addition, it worsens the outcome of potential future treatments, such as a corneal transplant. A corneal transplant is a treatment that many patients with severe corneal disease may ultimately need.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 10, 2010
Enrollment StartNov 1, 2010
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 15.6 years ago

Interventions

Pazopanib (5mg/ml)drug

Topical pazopanib, 4 times per day for 3 weeks